^
    Back
    Association details:
    Biomarker:KIAA1549-BRAF fusion + MET amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor) +
    Tabrecta (capmatinib) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Front Oncol
    Title:

    Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report

    Published date:
    03/18/2022
    Excerpt:
    ...a 67-year-old man was diagnosed with stage IV pulmonary poorly differentiated adenocarcinoma...NGS by FoundationOne® CDx revealed KIAA1549-BRAF fusion (Figure 1) and MET amplification...the treatment strategy was shifted to combination therapy with dabrafenib, trametinib, and capmatinib after multidisciplinary team discussion. Finally, the right pleural effusion subsided and remained stable for more than 6 months.
    DOI:
    https://doi.org/10.3389/fonc.2022.838798
    Test:
    FoundationOne® CDx